Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Vascular Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NOTCH3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NOTCH3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View NOTCH3 Products |
| Gene Delivery | NOTCH3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for conformation-dependent assays. |
View NOTCH3 Products |
| Benchmark Ab | Anti-NOTCH3 (Sequence of Tarextumab / PF-06650808) Recombinant positive control antibody. |
View NOTCH3 Products |
| Validator | NOTCH3 siRNA Set For knockdown verification in target-validation assays. |
View NOTCH3 Products |
| Related Target A | DLL4 Primary ligand for NOTCH3. Crucial for studying ligand-induced receptor activation and blocking assays. |
View DLL4 Products |
| Related Target B | JAG1 Alternative Notch ligand involved in tumor angiogenesis and synergistic notch pathway activation. |
View JAG1 Products |
| Related Target C | NOTCH1 Key family homolog. Required for counter-screening to ensure NOTCH3-specific selectivity and avoid GI toxicity. |
View NOTCH1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog NOTCH3 proteins available with >95% purity. |
| Subfamily counter-screening (NOTCH1/2/4) | Homolog panel proteins strictly verified by mass spectrometry and sequence-verified to ensure zero cross-contamination. |
| Lack of clinical benchmark controls | Sequence-verified Clinical Benchmark Antibodies (biosimilars) included in our portfolio. |
| False positives in binding assays | Sequence-verified siRNA sets included for target knockdown and specificity validation. |
Live NOTCH3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NOTCH3 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific antibodies. Because NOTCH3 is highly expressed in several aggressive solid tumors (including ovarian, triple-negative breast, and non-small cell lung cancers) as well as being the causative gene for CADASIL, it represents a high-value target. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective epitopes to avoid the severe gastrointestinal toxicities historically associated with pan-Notch inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Pfizer, Academic Institutes | Solid Tumors (Ovarian, NSCLC) | Internalization Assay (Need high-purity, native glycosylated ECD-Fc proteins) |
| Bispecific Antibody | Oncomed, Biopharma Pioneers | Angiogenesis & Tumor Stroma | Heterodimer Validation (Need cross-reactive ligand proteins like DLL4/JAG1) |
| Monoclonal Antibody (Selective) | Roche, Genentech, AbbVie | CADASIL, Solid Tumors | Selectivity Assay (Need NOTCH1/2/4 homolog panel for counter-screening) |